Pharmaceutical compositions that modulate HPTPbeta activity

Details Pharmaceutical compositions that modulate HPTPbeta activity Pharmaceutical compositions that modulate HPTPbeta activity

2007-04-17

2009-12-15

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

N-c doai

Reexamination Certificate

active

07632862

ABSTRACT:
HPTPbeta is useful as a target in screening agents effective for the treatment of angiogenesis mediated disorders.

REFERENCES:
patent: 4673641 (1987-06-01), George et al.
patent: 5424398 (1995-06-01), Middeldorp et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5807819 (1998-09-01), Cheng et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6589758 (2003-07-01), Zhu
patent: 6596722 (2003-07-01), Moltzen et al.
patent: 7226755 (2007-06-01), Peters et al.
patent: 7507568 (2009-03-01), Evdokimov et al.
patent: 2004/0167183 (2004-08-01), Klopfenstein et al.
patent: 2007/0299116 (2007-12-01), Gray
patent: 2008/0004267 (2008-01-01), Gray
patent: 2008/0108631 (2008-05-01), Gray
patent: WO 00/65085 (2000-11-01), None
patent: WO 00/65088 (2000-11-01), None
patent: WO 02/26774 (2002-04-01), None
Meadows; “Keeping Up With Drug Safety Information”; 2006; FDA Consumer magazine; http://www.fda.gov/fdac/features/2006/306—drugsafety.html, accessed Mar. 17, 2008.
Saliba; “Heparin in the treatment of burns: a review”; May 2001; Burns 27(4): 349-358; full text edition, pp. 1-16.
Suggitt et al.; “50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches”; 2005; Clinical Cancer Research; 11:971-981.
Daar; “Perspective: Emerging Resistance Profiles of Newly Approved Antiretroviral Drugs”; 2008; Topics in HIV Medicine; 16(4): 110-6.
U.S. Appl. No. 10/634,027, filed Aug. 4, 2003, Evdokimov et al.
Chanteau, S.H. et al., “Synthesis of Anthropomorphic Molecules: The NanoPutians,”J. Org. Chem. 2003, vol. 68, pp. 8750-8766.
Fachinger, G., et al., “Functional Interaction of Vascular Endothelial-Protein-Tyrosine Phosphatase with the Angiopoietin Receptor Tic-2”, Oncogene, 1999, vol. 18, pp. 5948-5953.
Gaits, F., et al., “Increase in Receptor-like Protein Tyrosine Phosphatase Activity and Expression Level on Density-Dependent Growth Arrest of Endothelial Cells”, Biochem. J., 1995, vol. 311, pp. 97-103.
Harder, K.W., et al., “Characterization and Kinetic Analysis of the Intraccllular Domain of Human Protein Tyrosine Phosphatase β (HPTPβ) Using Synthetic Phosphopeptides”, Biochem. J., 1994, vol. 296, pp. 395-401.
Hopkins, S.C. et al., “Inhibitors of Kinesin Activity from Structure-Based Computer Screening,”Biochemistry, 2000, vol. 39, pp. 2805-2814.
Huang et al., HCPTPA, a Protein tyrosine phosphotase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity, J. Biol. Chem. 1999, 53, 38183-38188.
Jones, G. et al., “Development and Validation of a Genetic Algorithm for Flexible Docking,”J. Mol. Biol. 1997, vol. 267, pp. 727-748.
Krueger, N.X., et al., “Structural Diversity and Evolution of Human Receptor-Like Protein Tyrosine Phosphatases”, The EMBRO J., 1990, vol. 9, No. 10, pp. 3241-3252.
Harder, K.W., et al., “Characterization and Kinetic Analysis of the Intraccllular Domain of Human Protein Tyrosine Phosphatase β (HPTPβ) Using Synthetic Phosphopeptides”, Biochem. J., 1994, vol. 296, pp. 395-401.
Rarey, M. et al., “A Fast Flexible Docking Method Using An Incremental Construction Algorithm,”J. Mol. Biol., 1996, vol. 261, pp. 470-489.
Skoichet, B.K. et al., “Lead Discovery Using Molecular Docking,”Chem. Biology, 2002, vol. 6, pp. 439-446.
Stahl, M. et al., “Detailed Analysis of Scoring Functions for Virtual Screening,”J. Med. Chem., 2001, vol. 44, pp. 1035-1042.
Wang, Y. et al., “Expressions and Characterization of Wild Type, Truncated, and Mutant Forms of the Intracellular Region of the Receptor-Like Protein Tyrosine Phosphatase HPTPβ”, The J. of Biological Chem., 1992, vol. 267, No. 23.
Wright, M.B. et al., “Protein-Tyrosine Phosphatases in the Vessel Wall Differential Expression After Acute Arterial Injury”, Arterioscler Thromb Vasc., 2000, pp. 1189-1198.
Annex, “Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,”Cardiovascular Research, 65(3):649-655 (2005).
Ardelt, “Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-α in a Rodent Experimental,”Stroke, 36:337-341 (2005).
Altschul et al., “Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs,”Nucleic Acids Res., 25(27):3389-3402 (1997).
Auerbach et al., “Angiogenesis Assays: A Critical Overview,”Clinical Chemistry, 49(1):32-40 (2003).
Barany et al., “Solid-phase Peptide Synthesis: A Silver Anniversary Report,”Int J. Peptide Protein Res., 30(6):705-739 (1987).
Bartlett et al., “Molecular Recognition in Chemical and Biological Problems; Cavet: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules,”Special Pub., Royal Chem. Soc., 78:182-196 (1989).
Bohm, “The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors,”J. Comuter-Aided. Molec. Design, 6(1):61-78 (1992).
Bussolino et al., “Molecular Mechanisms of Blood Vessel Formation,”Trends Biochem Sci. 22(7):251-256 (1997).
Carano et al., “Angiogenesis and Bone Repair,”Drug Discovery Today, 8(21):980-989 (2003).
Carvalho et al., “The Role of Angiogenesis in a Murine Tibial Model of Distraction Osteogenesis,”Bone. 34:849-861 (2004).
Cohen et al., “Molecular Modeling Software and Methods for Medicinal Chemistry,”J. Med. Chem., 33(3):883-894 (1990).
Flower, “Modelling G-Protein-Coupled Receptors for Drug Design,”Biochimica et Biophysica Acta, 1422:207-234 (1999).
Folkman, “Tumor Angiogenesis,”The Molecular Basis of Cancer(eds. Mendelsohn, J., Howley, P. M., Israel, M. A. & Liotta, L. A.) 10:206-232 (1995).
Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,”J. Med. Chem., 28(7):849-57 (1985).
Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing,”Proteins Struct. Funct. Genet. 8:195-202 (1990).
Henikoff et al., “Amino Acid Substitution Matrices from Protein Blocks,”Proc. Natl. Acad. Sci. USA89:10915-10919 (1992).
Itoh et al., “Purification and Characterization of the Catalytic Domains of the Human Receptor-Linked Protein Tyrosine Phosphatases HPTPβ, Leukocyte Common Antigen (LCA), and Leukocyte Common Antigen-Related Molecule (LAR),”Journal of Biological Chemistry, 267(17):12356-12363 (1992).
Keen, “Radioligand Binding Methods for Membrane Preparations and Intact cells,”Methods in Molecular Biology, 83:Receptor Signal Transduction Protocols, edited Humana Press Inc., Totoway N.J. (1997).
Kohler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature, 256:495-497 (1975).
Kugathasan et al, “Role of Angiopoietin-1 in Experimental and Human Pulmonary Arterial Hypertension,”Chest, 128(6):633S-642S (2005).
Kuntz et al., “A Geometric Approach to Macromolecule—Ligand Interactions,”J. Mol. Biol. 161:269-288 (1982).
Lin et al., “Inhibition of Tumor Angiogenesis Using a Soluble Receptor Establishes a Role for Tie2 in Pathologic Vascular Growth,”J. Clinical Invest., 100(8):2072-2078 (1997).
Ma et al., “RNase Protection Assay,”Methods, 10(3):273-8 (1996).
Merrifield, “Solid Phase Peptide Synthesism. I. The Synthesis of a Tetrapeptide,”J. Am. Chem. Soc., 85:2149-2154 (1963).
Miranker et al., “Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,”Proteins: Struc. Func. And Genectics, 11(1):29-34 (1991).
Navaza, “AMoRe: An Automated Package for Molecular Replacement,”J. Acta Cryst. A50

Affiliated with

Also associated with

Rating

Pharmaceutical compositions that modulate HPTPbeta activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions that modulate HPTPbeta activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions that modulate HPTPbeta activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4148156